Randomised, double-blind, placebo-controlled single ascending dose study investigating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of the research medication in healthy young and elderly men, and open-label three-period crossover food interaction study of the research medication in healthy elderly men

The research medication is a new medication developed for the treatment of
Parkinson*s disease.

- to examine the safety and tolerability of the research medication
- to examine how the research medication is absorbed, broken down and excreted
by the body.

This is a randomised, double-blind, placebo-controlled single ascending dose
study.

The study will start with a screening. At the screening a physical examination
will take place and a few other standard medical assessments will be performed
(ECG, vital signs). Furthermore a blood and urine sample will be taken for
laboratory tests and an alcohol breath test and drug screen will be done.

During the stay in the clinic the subject will receive the study medication and
on several time points blood will be taken and urine will be collected. The
subjects will be asked for possible side effects on regular basis. Furthermore
several safety assessments will be done frequently.

Finally, a follow-up visit will take place.

Possible side effects may include headache, nausea, vomiting, increased heart
rate and lowered blood pressure which could lead to dizziness (in particular
with fast standing up).

The doses are chosen from research in lab animals. The risks with these doses
is likely to be minimal, but as with all clinical drug studies, unforeseeable
adverse reactions could occur. In order to keep the risks as low as possible,
subjects will be monitored carefully during the whole study.